Articles From: Official who oversaw rocky Obamacare rollout is stepping down to Altice signals interest in buying Bouygues


2015/1/16
By Russ Britt, MarketWatch Tavenner to leave as head of Centers for Medicare and Medicaid Marilyn Tavenner, who oversaw the Centers for Medicare and Medicaid during one of the most tumultuous periods in its history, is stepping down as the agency's administrator, the agency said Friday.
Sign-up for Official who oversaw rocky Obamacare rollout is stepping down investment picks
2015/1/17
By Russ Britt, MarketWatch Eastwood picture on track to be his best-performing film Eastwood picture on track to be his best-performing film LOS ANGELES (MarketWatch)--The Martin Luther King holiday could prove to be a bonanza for Clint Eastwood's war drama "American Sniper"--perhaps finally lifting one of Oscar's eight best-picture nominees into bona fide hit status.
Sign-up for 'American Sniper': Oscar's only bona fide hit? investment picks
By Russ Britt, MarketWatch Stock leaps as new treatment leap past a testing step LOS ANGELES (MarketWatch) -- Plans by Biogen Idec Inc. to move directly from Phase I to Phase III testing on an Alzheimer's treatment boosted shares of the company nearly 7% early Tuesday.
Sign-up for Biogen Alzheimer's drug skips to Phase 3 testing investment picks
By Russ Britt, MarketWatch LOS ANGELES (MarketWatch) -- Reports that Lakeland Industries has booked 1 million orders for the hazardous-materials protective gear it produces for health-care workers treating Ebola patients handed the company's shares a 30%-plus spike Thursday.
Sign-up for Hazmat-suit maker's shares jump on Ebola orders investment picks
By Russ Britt, MarketWatch Stock jumps as new treatment leaps past a testing step LOS ANGELES (MarketWatch) -- Plans by Biogen Idec Inc. to move directly from Phase I to Phase III testing on an Alzheimer's treatment boosted shares of the company nearly 7% early Tuesday.
Sign-up for UPDATE: Biogen Alzheimer's drug skips to Phase 3 testing investment picks
By Russ Britt, MarketWatch LOS ANGELES (MarketWatch) -- Regeneron Pharmaceuticals Inc. tumbled by more than $21 a share in morning trade Tuesday after the drug maker surprised investors with disappointing sales of a key product and reported third-quarter earnings that fell below forecasts.
Sign-up for UPDATE: Regeneron skids on shortfall in Eylea sales investment picks
By Russ Britt, MarketWatch Anticipation now at fever pitch, analysts say LOS ANGELES (MarketWatch) -- The Sony Corp.
Sign-up for UPDATE: Sony remains likely to release controversial comedy 'The Interview' despite threat investment picks
By Russ Britt, MarketWatch Anticipation now at fever pitch for 'The Interview,' analysts say LOS ANGELES (MarketWatch) --The Sony Corp.
Sign-up for Sony likely to still release controversial comedy investment picks
By Russ Britt, MarketWatch After monthslong struggle, Valeant will drop Allergan buyout plan LOS ANGELES (MarketWatch) -- It seems Allergan Inc. doesn't have to worry about Valeant Pharmaceuticals International Inc. anymore.
Sign-up for Valeant says it won't meet Actavis's offer investment picks
By Russ Britt, MarketWatch LOS ANGELES (MarketWatch) -- Viacom Inc. is set to report fourth-quarter earnings on Thursday with high expectations from two key box-office successes during Hollywood's summer season.
Sign-up for What to look for in Viacom earnings investment picks
By Russ Britt, MarketWatch LOS ANGELES (MarketWatch) -- Walt Disney Co.'s shares have been moving like a freight train of late as have its earnings, and it seems this mouse will continue to roar.
Sign-up for UPDATE: What to look for in Disney earnings investment picks
By Russ Britt, MarketWatch LOS ANGELES (MarketWatch) -- When Time Warner Cable Inc. reports third-quarter earnings on Thursday, the answer some will be awaiting -- besides when and if it will be swallowed up by Comcast Corp.
Sign-up for What to look for in Time Warner Cable earnings investment picks
By Russ Britt, MarketWatch An expected drop in advertising revenue, coupled with increased expenses needed to bring Thursday night football games to broadcast television, could well leave investors disappointed when CBS Corp.
Sign-up for What to look for in CBS earnings investment picks
By Russ Britt, MarketWatch LOS ANGELES (MarketWatch) -- Walt Disney Co.'s shares have been moving like a freight train of late as have its earnings, and it seems this mouse will continue to roar.
Sign-up for What to look for in Disney earnings investment picks
By Russ Britt, MarketWatch LOS ANGELES (MarketWatch) -- Investors who saw a spinoff of consumer-products giant Kimberly-Clark Corp.
Sign-up for Ebola play Halyard Health stock gains are modest investment picks
By Russ Britt, MarketWatch LOS ANGELES (MarketWatch)-- Two earnings reports, coupled with a dose of internal drama, sent the shares of two drug makers tumbling Friday, with Salix Pharmaceuticals Ltd.
Sign-up for Drug companies Salix, Intercept reeling after earnings, drama investment picks
By Russ Britt, MarketWatch Media company had a good summer, but fall brought trouble LOS ANGELES (MarketWatch) -- Viacom Inc. is set to report fiscal fourth-quarter earnings on Thursday, ahead of the open, with high expectations from two key box-office successes during Hollywood's summer season.
Sign-up for UPDATE: What to look for in Viacom earnings investment picks
By Russ Britt, MarketWatch Media company had a good summer, but fall brought trouble LOS ANGELES (MarketWatch) -- Viacom Inc. is set to report fiscal fourth-quarter earnings on Thursday, ahead of the open, with high expectations from two key box-office successes during Hollywood's summer season.
Sign-up for UPDATE: What to look for in Viacom earnings investment picks
By Russ Britt, MarketWatch Actavis shares jump 5.5% while Allergan rises 1.4% LOS ANGELES (MarketWatch) -- This has got to be a new one in the merger game: the buyer's shares have gone up more than the company it's buying.
Sign-up for Actavis shares outpace buyout target's gains investment picks
By Russ Britt, MarketWatch Fox Searchlight gets most movie nods; HBO leads in TV LOS ANGELES (MarketWatch) -- "Birdman," the feature film about a washed-up actor who tries to reclaim past glory by directing a Broadway play, and "Fargo," the miniseries reconstituting the disturbing 1996 film that garnered its own awards, led all prospects in Golden Globe nominations on Thursday.
Sign-up for 'Birdman,' 'Fargo' lead Golden Globe nominations investment picks
By Russ Britt, MarketWatch More competitors in the market doesn't equate to lower prices SAN FRANCISCO (MarketWatch) -- If you're looking for drug makers to start discounting those pricey, $1,000-a-pill remedies for hepatitis C soon, prepare to be disappointed.
Sign-up for Don't look for pricey hepatitis drugs to come down investment picks
By Russ Britt, MarketWatch Treatment designed to help kidney patients accept new organs Shares of Alexion Pharmaceuticals Inc. fell in after-hours trades after the drug maker said its plan to use its Soliris blood-clotting treatment to help kidney transplant patients accept their new organ didn't meet its goals in the second phase of testing.
Sign-up for Alexion tumbles on failed transplant drug trial investment picks
By Russ Britt, MarketWatch Retail giant to focus on biotech firm's $1,000-a-day pills LOS ANGELES (MarketWatch) -- Shares of Gilead Sciences Inc. were up more than 2% Monday after the biotechnology giant scored an exclusive rights deal with the nation's largest drug-store chain, CVS Health Corp., for two Hepatitis C treatments that cost $1,000 per pill or more.
Sign-up for Gilead, CVS strike deal on Hepatitis C drugs investment picks
By Russ Britt, MarketWatch Boston Scientific turning around, up more than 4% on upgrade LOS ANGELES (MarketWatch)-- A slew of stock upgrades, improved outlooks, positive drug trials and an overall market rally boosted the health-care sector Thursday.
Sign-up for Drug trials, upgrades boost health-care sector investment picks
By Russ Britt, MarketWatch Studio follows lead of theater owners who delay its release Sony Pictures Entertainment will cancel its planned Christmas Day release of "The Interview," the subject of recent hack attacks and violent threats against the company and theater owners, the studio said Wednesday.
Sign-up for UPDATE: Sony cancels Christmas debut of 'The Interview' investment picks
By Russ Britt, MarketWatch Studio follows lead of theater owners who delay its release Sony Pictures Entertainment will cancel its planned Christmas Day release of "The Interview," the subject of recent hack attacks and violent threats against the company and theater owners, the studio said Wednesday.
Sign-up for Sony cancels Christmas debut of 'The Interview' investment picks
By Russ Britt, MarketWatch Process used to inactivate pathogens prior to transfusions LOS ANGELES (MarketWatch) -- Shares of tiny biomedical products company Cerus Corp.
Sign-up for Cerus jumps on FDA OK for plasma treatment investment picks
2015/1/14
By Russ Garland Powered by giant funding rounds for tech companies such as Uber Technologies Inc., U.S. venture-capital investment jumped 47% in 2014, as investment in later-stage deals hit an all-time high.
Sign-up for Venture Investments Soar, Driven by Later-Stage Deals investment picks
2014/11/20
By Ruth Bender, Eyk Henning and Shayndi RaiceFresenius, Permira make joint bid German health-care group Fresenius SE & Co.
Sign-up for Danone gets bid for medical-nutrition business investment picks
2014/11/21
By Ruth Bender BARCELONA --
Sign-up for Altice signals interest in buying Bouygues investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Official who oversaw rocky Obamacare rollout is stepping down to Altice signals interest in buying Bouygues
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent